Effect of N-acetylcysteine on prevention of contrast-associated acute kidney injury in patients with STEMI undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomised controlled trials
| Autor: | LingYu Zhang, Yong Liu, Jin Liu, Shiqun Chen, Hao Huang, Li Lei, Liwei Liu, Zhaodong Guo, Ji-yan Chen, Yan Xue, Qingbo Xu, Yingzhong Lin, Jianhong Tao, Keng Wu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | BMJ Open, Vol 10, Iss 10 (2020) |
| Druh dokumentu: | article |
| ISSN: | 2020-0390 2044-6055 |
| DOI: | 10.1136/bmjopen-2020-039009 |
| Popis: | Objective Several studies evaluating the preventive effect of N-acetylcysteine (NAC) on contrast-associated acute kidney injury (CA-AKI) among patients with ST segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI) have suggested inconsistent results and that a systematic review and meta-analysis should be performed.Design Systematic review and meta-analysis.Data sources PubMed, MEDLINE, EMBASE, ClinicalTrials.gov and the Cochrane Central databases were searched from inception to 15 November 2019.Eligibility criteria Randomised controlled trials assessing use of NAC compared with non-use of NAC (eg, placebo) in preventing CA-AKI in patients with STEMI following PPCI were included.Data synthesis Relative risks with 95% CIs were pooled using a random-effects model. Evidence level of conclusions was assessed by Cochrane GRADE measure.Results Seven trials including 1710 patients were identified. Compared with non-use of NAC, use of NAC significantly reduced the incidence of CA-AKI by 49% (risk ratio (RR) 0.51, 95% CI 0.31 to 0.82, p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|